Osteoarthritis Pain - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 140 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Osteoarthritis Pain - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Osteoarthritis Pain - Pipeline Review, H2 2014', provides an overview of the Osteoarthritis Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Osteoarthritis Pain Overview 10
Therapeutics Development 11
Pipeline Products for Osteoarthritis Pain - Overview 11
Pipeline Products for Osteoarthritis Pain - Comparative Analysis 12
Osteoarthritis Pain - Therapeutics under Development by Companies 13
Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes 16
Osteoarthritis Pain - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Osteoarthritis Pain - Products under Development by Companies 21
Osteoarthritis Pain - Products under Investigation by Universities/Institutes 23
Osteoarthritis Pain - Companies Involved in Therapeutics Development 24
Boehringer Ingelheim GmbH 24
Allergan, Inc. 25
Eli Lilly and Company 26
Pfizer Inc. 27
Purdue Pharma L.P. 28
Teva Pharmaceutical Industries Limited 29
BioChemics, Inc. 30
Addex Therapeutics Ltd 31
Nuvo Research Inc. 32
Pozen, Inc. 33
Futura Medical plc 34
AcurePharma AB 35
Rottapharm SpA 36
QRxPharma Limited 37
Iroko Pharmaceuticals, LLC 38
Antibe Therapeutics, Inc. 39
Flexion Therapeutics, Inc. 40
Afferent Pharmaceuticals, Inc. 41
iCeutica, Inc. 42
Ampio Pharmaceuticals, Inc. 43
AbbVie Inc. 44
Akron Molecules AG 45
Osteoarthritis Pain - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 51
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
hydrocodone bitartrate ER - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
duloxetine hydrochloride DR - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
meloxicam nanoformulation - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Ampion - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
triamcinolone acetonide SR - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ART-144 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
CR-4056 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
(morphine + oxycodone) CR - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AF-219 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
onabotulinumtoxinA - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
LY-2951742 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
AMAP-102 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RQ-00000008 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
FX-005 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ibuprofen - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
naproxen nanoformulation - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
OLT-1177 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
grapiprant - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
V-116517 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
AKR-202 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
(lidocaine + tetracaine) - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
PA-65020 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
ATB-346 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
BI-1026706 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule to Antagonize 5-HT2 Receptor for Immunology, Central Nervous System and Dermatology - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ADX-71441 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
ibuprofen - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
celecoxib nanoformulation - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ELS-130 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
TASS Project - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
CRB-0089 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
NEO-6860 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
A-889425 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
IPNIB - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
AQU-010 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
NEO-5024 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Small Molecules to Inhibit PDE2 for Osteoarthritis Pain - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
CRB-0022 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
TPR-100-Rx - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
VLNX-4975 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Osteoarthritis Pain - Recent Pipeline Updates 110
Osteoarthritis Pain - Dormant Projects 131
Osteoarthritis Pain - Discontinued Products 132
Osteoarthritis Pain - Product Development Milestones 133
Featured News & Press Releases 133
Jun 19, 2014: Antibe Therapeutics Receives Approval from Health Canada to Begin Human Clinical Testing 133
May 23, 2014: Phase 3 Data from Iroko Pharmaceutical's SoluMatrix NSAID Portfolio to be Presented at EULAR 2014 133
May 22, 2014: Antibe Therapeutics Announces Submission of Clinical Trial Application to Health Canada For ATB-346 134
Apr 09, 2014: Results from the 20 weeks extension of the Ampion SPRING study to be presented at the Western Orthopedic Association Conference 134
Mar 12, 2014: Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent 135
Jul 01, 2013: Futura Medical's Franchise now includes TPR100 plus programmes using ibuprofen and methyl salicylate 135
Jun 03, 2013: Ampio Pharma Provides Update On SPRING Trial Of Ampion For Treatment Of Osteoarthritis Of Knee 136
Mar 15, 2013: Bone Medical Re-affirms Strategy To Pursue Oral Calcitonin Program 137
Nov 07, 2012: Eli Lilly Receives Health Canada Approval For Cymbalta For Management Of Osteoarthritis Knee Pain 137
Nov 06, 2012: Array BioPharma To Present Phase II Results Of ARRY-797 At 2012 American College Of Rheumatology Annual Meeting 138
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 140
Disclaimer 140

List of Tables
Number of Products under Development for Osteoarthritis Pain, H2 2014 11
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2014 23
Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2014 24
Osteoarthritis Pain - Pipeline by Allergan, Inc., H2 2014 25
Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H2 2014 26
Osteoarthritis Pain - Pipeline by Pfizer Inc., H2 2014 27
Osteoarthritis Pain - Pipeline by Purdue Pharma L.P., H2 2014 28
Osteoarthritis Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 29
Osteoarthritis Pain - Pipeline by BioChemics, Inc., H2 2014 30
Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H2 2014 31
Osteoarthritis Pain - Pipeline by Nuvo Research Inc., H2 2014 32
Osteoarthritis Pain - Pipeline by Pozen, Inc., H2 2014 33
Osteoarthritis Pain - Pipeline by Futura Medical plc, H2 2014 34
Osteoarthritis Pain - Pipeline by AcurePharma AB, H2 2014 35
Osteoarthritis Pain - Pipeline by Rottapharm SpA, H2 2014 36
Osteoarthritis Pain - Pipeline by QRxPharma Limited, H2 2014 37
Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2014 38
Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H2 2014 39
Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H2 2014 40
Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H2 2014 41
Osteoarthritis Pain - Pipeline by iCeutica, Inc., H2 2014 42
Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals, Inc., H2 2014 43
Osteoarthritis Pain - Pipeline by AbbVie Inc., H2 2014 44
Osteoarthritis Pain - Pipeline by Akron Molecules AG, H2 2014 45
Assessment by Monotherapy Products, H2 2014 46
Assessment by Combination Products, H2 2014 47
Number of Products by Stage and Target, H2 2014 50
Number of Products by Stage and Mechanism of Action, H2 2014 53
Number of Products by Stage and Route of Administration, H2 2014 56
Number of Products by Stage and Molecule Type, H2 2014 58
Osteoarthritis Pain Therapeutics - Recent Pipeline Updates, H2 2014 110
Osteoarthritis Pain - Dormant Projects, H2 2014 131
Osteoarthritis Pain - Discontinued Products, H2 2014 132